

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 January 2008 (24.01.2008)

PCT

(10) International Publication Number  
**WO 2008/009932 A1**

(51) International Patent Classification:  
A61B 5/00 (2006.01)

(21) International Application Number:  
PCT/GB2007/002716

(22) International Filing Date: 18 July 2007 (18.07.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0614218.6 18 July 2006 (18.07.2006) GB

(71) Applicant (for all designated States except US): UWS  
VENTURES LIMITED [GB/GB]; Digital Technium,  
Singleton Park, Swansea SA2 8PP (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): WILLSHAW, Peter  
[GB/GB]; School of Health Science, Swansea University,  
Swansea SA2 8PP (GB).

(74) Agent: STRACHAN, Victoria, Jane; Urquhart-Dykes &  
Lord LLP, Churchill House, Churchill Way, Cardiff CF10  
2HH (GB).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG,  
ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK,  
LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW,  
MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,  
PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,  
ZM, ZW.


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL,  
PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DEVICE AND METHOD FOR ALTERING CARDIAC ACTIVITY



(57) Abstract: A device for altering cardiac activity, said device comprising a neck engaging member, said neck engaging member having at least one pressure applicator provided as a predefined area which in use comes into contact with and occludes or partially occludes at least one carotid artery, said device including a control mechanism which is operable to cause the pressure applicator to rapidly occlude or partially occlude the artery in order to provoke heart rate turbulence.

WO 2008/009932 A1

Device and Method for Altering Cardiac Activity

The invention relates to a device and method for altering  
5 cardiac activity so that information obtained from  
monitoring the activity of the heart can be used in the  
prediction of cardiac events. In particular but not  
exclusively, the invention relates to a device and method  
for non-invasively provoking, when required, heart rate  
10 changes in individuals such as humans or animals by the  
occlusion or partial occlusion of one or more carotid  
arteries of that individual.

The heart comprises two thin-walled atrial chambers,  
15 which provide a left and a right atrial chamber and these  
chambers sit above the two thicker walled and larger,  
left and right ventricular chambers of the heart. The  
right ventricular chamber pumps blood to the lungs, while  
the left ventricular chamber pumps blood to the rest of  
20 the body. The atrial chambers pump blood to fill the two  
ventricular chambers before they contract to pump blood  
to the body. The heart has its own natural or built in  
pacemaker called the sinoatrial node (also called the SA  
node or sinus node). The SA node sends impulses to the  
25 right and left atrial chambers so they are caused to  
beat. Impulses are then sent via the atrioventricular  
(AV) node to the ventricular chambers causing them to  
beat a split second later.

30 The carotid arteries in the neck just below the angle of  
the jaw contain nerve endings within their walls, which  
are stretched by each blood pressure pulse. These nerves  
are called baroreceptors and with each pulse of pressure

-2-

they send impulses to the brain centres involved in blood pressure control. High pressures produce more nerve impulses and low pressures produce fewer impulses. Under normal conditions, this nerve traffic controls the heart to produce the normal heart rate of around 70 beats per minute. If the pressure rises, the heart is controlled such that the heart rate falls. However, if the blood pressure falls as a result of a fall in the heart rate due to missed beats, the nerve traffic is inhibited and the heart speeds up. When the heart begins beating normally again following a 'compensatory pause' and the normal pattern of blood pressure pulses is restored, the heart rate slows down again and the rate may even fall below that present before the premature ventricular contraction (PVC). The temporal pattern of these heart rate changes is Heart Rate Turbulence (HRT).

Changes in the regular beat of the heart (arrhythmias) can occur and they tend to occur more commonly in individuals as they become older and in particular in middle age, although they may occur in younger individuals. In younger individuals, arrhythmias may be due to genetically inherited heart defects. Arrhythmias may be associated with and provide an indication of heart disease, which could lead to a heart attack (myocardial infarction). A heart attack occurs as the result of muscle cells in the heart dying and as result of the lack of supply of oxygen to the heart and nutrients. Heart attacks may be due to poor health due to the blocking of arteries or poor circulation but there may also be genetic defects in the individual, which cause heart

-3-

muscle to be damaged. If the heart disease goes undetected the individual has an increased risk of death.

Abnormalities in the heart rhythm have been controlled by  
5 a range of methods, including prescribing drugs to control the heart rate, using devices such as automatic pacemakers and / or defibrillators, which are implanted in the patient or alternatively surgery can be used. These techniques are usually used when the heart disease  
10 is more advanced as treatment is usually sought after an event such as a heart attack, which demonstrates that there is already damage to the heart tissue. An example of a device that is inserted in the body to control heart rate is discussed in US 5222980, which describes an  
15 implantable heart assist device including an extra-aortic balloon pump which uses stimulation of nearby muscles to assist heart activity. However, there is patient trauma when inserting such devices in the body and the patient, who has to undergo an operation so that the device can be  
20 inserted. When undergoing such operations, patients need to be anaesthetized, which may have particular risks for patients with heart problems.

It has become apparent that predicting whether an  
25 individual is likely to have a cardiac event is a preferable way to dealing with heart disease by treating a person once the heart disease has progressed to a more serious stage and where there may be more pronounced damage to the heart. If treatment can be given as early  
30 as possible, then this has the benefit of maintaining the health of the individual and also avoids costs by reducing the reliance on costly forms of treatment such as surgery.

-4-

Investigations have been made into how the heart can be monitored to see if there is a likelihood of a cardiac event such as a heart attack occurring.

5

Schmidt et al (in Heart Rhythm 2004 pp732-738, 1999) were the first to describe Heart Rate Turbulence (HRT) as a way of predicting Heart Disease. HRT refers to the changes in heart rate following a premature ventricular contraction (PVC) of the left ventricle. The changes in heart rate are characterised by two parameters, turbulence onset (TO) and turbulence slope (TS). These parameters were shown to be powerful predictors of subsequent cardiac events in patients who had suffered a myocardial infarction. PVCs occur spontaneously even in healthy individuals, who often refer to them using the expression 'my heart missed a beat'.

To date, measuring premature ventricular contractions necessary for the calculation of HRT parameters are almost universally obtained from 24hour recordings using an Electrocardiogram (ECG), where the patient is fitted with a small highly portable ECG recorder known as a Holter. With luck, the patient will display sufficient PVCs to allow HRT to be calculated. However, it has been shown that in this 24hour time frame, not all people will show PVCs and so individuals that may be at risk from heart disease could go undetected. An example of this is that in studies it has been found that in a sample of 110 healthy volunteers only 43 showed PVCs in their 24 Hr Holter recording i.e. 39%, so illustrating that many individuals with potential heart disease are not diagnosed. Also, there is the disadvantage that because

-5-

monitoring occurs over a relatively long period that individuals may not want to use the monitoring device because it could impinge on their lifestyle, for example if they want to indulge in activities such as swimming.

5

To overcome the disadvantages of long periods of monitoring it has been suggested that HRT in patients is studied in patients when fitted with pacemakers or with programmable defibrillators. However, this has the disadvantage that monitoring is only being carried out for individuals that warrant the need for a defibrillator, i.e. their heart disease may well be advanced because health authorities are unlikely to go to the expense of implanting equipment where it is not vital to do so. Also there is an increased risk to the patient in that they have to undergo surgery for the device to be implanted.

10  
15

Given the clinical importance of HRT as a predictor of subsequent cardiac events but the difficulty of obtaining sufficient PVCs from most patients, the present invention seeks to address the identified need for developing a device or method which is capable of provoking at will the same heart rate changes as those observed following a premature ventricular contraction. The essence of such a device would be to prevent or attenuate the carotid baroreceptor response to one or more pressure pulses i.e. to make the baroreceptors 'miss a beat' or 'miss' more than one beat.

20  
25

30

The idea of loading and unloading the carotid baroreceptors by applying neck suction and neck pressure respectively is not new.

-6-

Devices that have been used until now have employed compression and suction of the neck tissues using a transmission fluid between a chamber containing the fluid  
5 and the neck tissues. The known devices involve compressing the neck tissue for a number of seconds in order to evoke a steady-state response but there is no compression that is synchronised with the R-wave associated with cardiac activity. The R wave is shown as  
10 a spike on an ECG print out and indicates the point at which the heart ventricles are about to eject blood.

Devices have been developed where a moulded neck chamber is connected to a bellows system and is placed around the  
15 neck. The bellows generates positive pressure on the neck and makes a beat-by-beat transition to negative pressure over about 10 beats in a step-like fashion with each step transition being triggered by an R-wave measured from cardiac activity. The objective of this  
20 device was to generate a baroreceptor sensitivity curve over a wide range of pressures. However, this device does not provoke HRT because of the slow delivery of pressure and it is not capable of producing very fast changes of neck pressure to provoke a response that could  
25 be used to measure the risk of cardiac disease.

The current invention seeks to overcome the problems associated with the prior art by providing a device and method that can provoke heart rate changes at will  
30 without harming the individual.

According to the present invention there is provided a device for altering cardiac activity, said device

-7-

comprising a neck engaging member, said neck engaging member having at least one pressure applicator provided as a predefined area which in use comes into contact with and occludes or partially occludes at least one carotid artery, said device including a control mechanism which is operable to cause the pressure applicator to rapidly occlude or partially occlude the at least one carotid artery in order to provoke heart rate turbulence.

10 It is preferred that the device includes a control mechanism that causes the pressure applicator to occlude or partially occlude the at least one carotid artery and release therefore after a predetermined period of time.

15 It is envisaged that the occlusion or partial occlusion of the at least one carotid artery occurs is achieved within a period of a few milliseconds following the command to occlude or partially occlude. The time periods are typically 2, 3, 4, 5 or 10 or 20 or more  
20 milliseconds and that the time period during which the occlusion or partial occlusion is maintained is of one or more cardiac cycles in duration.

Preferably the neck engaging member device comprises a  
25 cuff that is placed around the neck of the individual, with the pressure applicator being aligned with the at least one carotid artery. The pressure applicator may comprise an inflatable balloon. The balloon can be inflated with a liquid or gas once in position with a  
30 carotid artery. Alternatively, the pressure applicator is a mechanical foot that is brought into contact with and presses against the one or more carotid arteries to fully or partially occlude them.

-8-

In a further arrangement, the neck engaging member comprises one or more arms that come into contact with the one or more carotid arteries.

5

In a preferred arrangement, the neck engaging member includes a sensor, which detects the carotid pulse when the pressure applicator is positioned over the carotid artery. By having locating means, such as a sensor, this  
10 allows health care professionals to easily position the neck engaging member such as the cuff or arms in the correct location for the carotid artery to be occluded or partially occluded.

15 In an alternative arrangement, visible indicators are present so that the neck engaging member can be aligned with the at least one carotid artery.

It is envisaged that the pressure applicator is a  
20 mechanical foot that is brought into contact with the at least one carotid artery.

Preferably, the control mechanism is associated with a cardiac monitoring sensor to detect the R-wave associated  
25 with cardiac activity. The cardiac monitoring sensor is used to measure the time delay between the R-wave and ventricular ejection into the arterial system. This is of the order of substantially 50 milliseconds. Pressure must be applied as soon as possible following the R-wave  
30 to prevent the arterial pulse from arriving at the carotid sinus or to attenuate the magnitude of such pulse at the carotid sinus.

-9-

It is envisaged that the cardiac monitoring sensor is in communication with an actuator that is operable to cause the pressure applicator to come into contact with the at least one carotid artery following detection of the R-wave.  
5

In a preferred arrangement, the activation of the actuator is triggered by detection of the R-wave followed by which the actuator is caused to release so that zero pressure is applied to the at least one carotid artery.  
10

It is preferred that the actuator is a voice coil actuator. As previously mentioned, the pressure applicator comes into contact with the at least one carotid artery within a few milliseconds following the detected R-wave.  
15

In a preferred arrangement, the device includes a pressure measuring device that monitors the pressure of the pressure inducing device against the carotid artery.  
20

The pressure measuring device is provided as a manometer.

It is envisaged that the pressure measuring device provides a pressure feedback signal as controller to a control system for the sensor for the pressure applicator which is compared with a desired pressure reference signal. The use of a reference signal for the pressure applied is a safety feature which allows the force developed by an actuator for the pressure applicator to be expressed in terms of pressure in a controlled fashion.  
25  
30

-10-

In one embodiment, the reference signal is limited.

In another embodiment, the current to the voice coil  
5 actuator is limited.

It is envisaged that both of these factors could be used  
to limit the pressure applied by the device.

10 It is preferred that the pressure applicator is  
associated with an ultrasound doppler probe resting on  
the neck to measure flow changes in the artery  
accompanying the pressure manoeuvre. The Doppler probe  
has a particular benefit in that it can measure for the  
15 presence of arterial plaques. In individuals with  
circulatory diseases, plaques may be dislodged from the  
walls of arteries and if this occurs, there is the risk  
of the plaque lodging in part of the circulatory system  
and causing blockages which if they occurred in organs  
20 such as the body or heart could kill an individual. The  
use of the Doppler probe would detect changes in the  
arterial wall structure and if there was a risk that the  
plaque is about to be dislodged, then use of the device  
could be halted.

25

It is envisaged that the device includes a pressure  
limiter. The use of a device that limits the pressure  
applied to the neck avoid the carotid artery being  
compressed too strongly or for too long a time period,  
30 which could disrupt blood flow in the individual.

Although the invention has been described with reference  
to the occlusion or partial occlusion of one carotid

-11-

artery, both the left and right carotid arteries could be occluded or partially occluded. It is envisaged that the arteries are occluded or partially occluded substantially simultaneously but they may also be occluded or partially  
5 occluded sequentially.

Further, the invention has applications not only in monitoring the heart condition of humans, but also it can be used in the monitoring of animals. In particular, the  
10 invention has applications in the monitoring of valuable breeding stock such as horses, dogs or cattle where it is undesirable that genetic heart complaints are passed on.

According to a further embodiment of the invention, there  
15 is provided a method of occluding or partially occluding the carotid artery, said method comprising applying a neck engaging member to an individual's neck such that at least one pressure applicator provided as a predefined area comes into contact with at least one carotid artery,  
20 operating a control mechanism to cause the pressure applicator to rapidly occlude or partially occlude the at least one carotid artery in order to provoke heart rate turbulence.

25 Preferably the control mechanism is caused to occlude or partially occlude the at least one carotid artery and release therefore after a predetermined period of time.

It is envisaged that in a preferred arrangement, the  
30 device is caused to occlude or partially occlude the at least one carotid artery within milliseconds, typically 1

-12-

or more milliseconds and more typically within 5 to 10, 15 to 20 or more milliseconds.

An embodiment of the invention will now be described by way of example only with reference to the accompanying figures in which:

Figure 1: shows the position of the carotid arteries for a human;

10

Figure 2: shows a dissected view of the human heart with the position of the carotid arteries and baroreceptors in the aortic arch;

Figure 3: shows a pair of traces with the upper trace showing the electrical activity of the heart over time via using an ECG reading. The lower trace shows blood pressure over time;

Figure 4: shows the effect of applying pressure and not applying pressure to the carotid artery over time;

Figure 5: shows a device for altering cardiac activity according to a first embodiment of the invention;

25

Figure 6: shows a device for altering cardiac activity according to a second embodiment of the invention;

Figure 7a: shows a schematic view of a further embodiment of the invention showing a device for altering cardiac activity;

30

-13-

Figure 7b: shows a cross sectional view along A-A of figure 7a; and

5 Figure 8: shows a schematic view of a device according to the invention with safety and control features for operation of the device.

As shown in Figure 1, the carotid arteries are situated  
10 in the neck of an individual. The figure shows one side of the neck with the external carotid artery being shown as 1, the internal carotid artery is shown a 2, while the common carotid artery is shown as 3. There are left and right carotid arteries as shown in Figure 2. The right  
15 common carotid artery is shown as 4, while the left carotid artery is shown as 5. The trachea is shown as 6, while the heart is shown at 7. On the aortic arch, there is a baroreceptor area 8.

20 The device of the present invention is designed to increase neck pressure in a controlled way for a single cardiac cycle thus unloading the baroreceptors for one beat and so simulating the pressure changes associated with a PVC to provoke HRT.

25

As shown in Figure 3, the electrical activity of the heart (the ECG) is measured. The sharp upward spikes are known as R-waves and immediately precede ventricular contraction, which then normally causes ejection of blood  
30 from the heart into the arterial system. As shown in the figure a premature contraction has occurred and is labelled PVB. The lower trace shows the arterial pressure. The timescale is in seconds. Premature beats

-14-

shown occur without producing ejection of blood from the ventricle and so blood pressure continues to fall before the next ejective beat begins the process of restoration of the normal pressure profile. This has the effect of  
5 the individual feeling that their heart has "missed a beat".

Figure 4 shows an electrocardiogram over time with the top line showing time in 100 millisecond intervals (a).  
10 The second line is the electrocardiogram trace over that time (b). The third line shows the intervals at which pressure is applied to the carotid artery over time (c). The bottom line shows the carotid pulse in the absence of pressure application (solid line -d) and the expected  
15 carotid pressure trajectory in the presence of applied pressure (dotted line - e). The values for HRT are not expressed as changes in heart rate but are expressed as the inverse of rate i.e. beat-to-beat interval known as R-R interval. The R-R intervals immediately precede  
20 ventricular contraction and ejection of blood from the heart. When the R-R intervals are plotted against time, before and after the PVC, heart rate turbulence is clearly evident by calculation of the turbulence onset (TO) and turbulence slope (TS). Turbulence onset  
25 quantifies shortening of RR interval, while Turbulence Slope is the greatest of slopes fitted to consecutive RR intervals after the VPC. Therefore the generation of a VPC is important to calculate these values.

30 As shown in Figure 5 a device which can be used to provoke PVC according to the present invention is generally shown as 9 in Figure 5, the device comprises a

-15-

neck engaging member such as a cuff 10 which can encircle the neck. Preferably, the cuff is made of material that can be washed and also which has a degree of flexibility to accommodate different neck sizes. The cuff can be  
5 fastened to the neck either by way of ties at either end of the cuff or by using hook and loop fastening such as Velcro® on the ends of the cuff. Positioned at defined locations 11a, 11b are pressure engaging pressure  
10 applicators which can be positioned so that they come into contact with the carotid artery on either side of the neck of an individual as shown in Figure 1. The pressure applicators in this case comprise balloon type members which can be inflated and deflated when in  
15 contact with the carotid arteries to cause occlusion or partial occlusion and release from the arteries. Also shown, are visual indicators 12 which a healthcare professional can use to align the pressure applicators with the carotid arteries of the neck of a person. In an  
20 alternative arrangement, or in combination with the visual indicators, there may be sensors 13 which can sense a pulse at the carotid arteries and provide a signal which may be either audible or visible or a combination of both so that when the pressure applicators are correctly positioned over the carotid arteries, the  
25 process of occluding the arteries can be started. Although balloon type pressure applicators are shown, these applicators could be for example mechanical feet which have actuators to bring them into contact with the carotid artery or alternatively, may be provided as  
30 protrusions which lie outside the plain of the neck engaging member 10 such that when the cuff is tightened,

-16-

the pressure applicators press against the carotid artery.

The operation of the device is precisely monitored so  
5 that the application of pressure occurs at just the right  
time and for just the right length of time to provoke a  
cardiac event. A control mechanism 14 can be used to  
detect R-waves associated with cardiac activity and on  
detection of the R-wave can cause actuators to apply  
10 pressure to the carotid arteries via the pressure  
applicator. The control mechanism may itself control the  
pressure applied and the length of time applied or  
alternatively, it can be associated with a separate  
control with which it interacts to make sure that the  
15 pressure is applied in the correct way to provoke a HRT  
response. Typically, pressure on the neck is maintained  
at less than 40 millimetres of mercury because above this  
level, there may be discomfort to the individual.

20 The control mechanism 14 is in communication with a  
number of controllers or sensors for example there is a  
pressure sensor which can detect the carotid pulse when  
the pressure applicator is positioned over the carotid  
artery and this allows for precise alignment of the  
25 pressure applicators with the carotid arteries and also,  
the sensor can include means to monitor the pulse rate of  
the individual. For example if the pulse rate is  
particularly slow or weak, then the pressure applied by  
the occlusion or partial occlusion device can be altered  
30 so that less pressure is applied to the neck which  
reduces the possible damage to arteries. The sensor or  
an alternative sensor can also be used to detect the R-  
wave so that pressure can be applied once this has

-17-

occurred. The R-wave can act as a trigger mechanism for an actuator which causes the pressure applicator to come into contact with the at least one carotid artery. Typically, the sensor is a solid state sensor but other  
5 pressure sensors could be used which the skilled person would understand would be applicable to the invention.

While occlusion or partial occlusion occurs to the arteries, pressure is measured for example through a  
10 pressure measuring device which measures the pressure of the pressure applicator against the carotid artery and this for example may be measured using a manometer. However, other pressure measuring devices could be used.

15 There is a control system in communication with the control mechanism which can receive pressure feedback from the pressure measuring device so that this can be compared with data such as a reference signal to ensure that the occlusion or partial occlusion of the carotid  
20 artery is within acceptable predetermined limits. If it is detected that the pressure is too great, the control mechanism can release the pressure of the pressure applicator. There is also an additional safety mechanism such that should the device fail, the application of  
25 pressure would be ceased immediately. Included as part of the safety feature are limiters for current value so that a reduction in current limits the activity of the actuator to reduce pressure applied to the carotid artery. A further desirable feature is the use of an  
30 ultrasound Doppler probe to monitor the state of the artery walls and detect should material be dislodged from the artery walls such that if this is detected, an alarm can be emitted and healthcare professionals would be

-18-

alerted to the fact that they may need to provide clot reducing drugs to minimise the risk of damage to the individual.

5 Figure 6 shows a variation of the device shown in Figure 5 where arms 15 which are in contact with an actuator 16 come into contact with the neck at the carotid artery region. The arms 15 provided as mechanical arms that are hinged at point 17. A control equivalent to that as  
10 shown in Figure 5 as 14 also controls the activity of the device. The device may be held by a healthcare professional or placed on a stand and the individual puts his or her neck between the arms and the arms are caused to move towards and abut against the neck of the  
15 individual. This is the first stage of operation. Following this controlled pressure can then be applied to the neck. The control mechanism controls delivery of pressure to the arms so that the arteries are occluded or partially occluded.

20

Figure 7a shows a device which includes a neck cuff type arrangement for securing to the neck as shown in Figure 5 but which includes a mechanical foot type arrangement for occluding or partially occluding the carotid arteries.

25

The device comprises a cuff 10 for encircling the neck and at either end of the cuff there are areas of hook and loop, otherwise known as Velcro<sup>®</sup> fasteners (10a, 10b). There is a pressure foot support unit 18, which has  
30 flanged slots 19, which can receive a pressure foot (shown in Figure 7b).

-19-

As shown in Figure 7b, the device shown in Figure 7a from side on includes the fixed part 20 of a voice coil actuator. This is arranged in or on the cuff 10 to be  
5 remote from the part of the device i.e. the foot that comes into contact with the individual's neck.

The moving element 21 of the voice coil actuator can move towards and away from the pressure foot 22 that comes  
10 into contact with the or both carotid arteries. Associated with the pressure foot 22 is an ultrasound probe 23 which can detect events in the carotid arteries such as pulse or the loosening of plaque material as well as blood flow. There is also a pressure sensor 24 which  
15 can detect the pressure being applied to the individual's neck and which is associated with a controller so the pressure is only applied within certain defined parameters or limits.

20 Moving on to Figure 8, this diagram represents a schematic arrangement of the safety features and controls that may be used with a device according to the invention. The controls can be used with the balloon type occlusion device of Figure 5, the mechanical arm  
25 type device of Figure 6 or the cuff and mechanical foot type arrangement as shown in Figures 7a and 7b.

The carotid arteries of the neck of an individual are shown as A. A neck cuff is placed around the neck (not  
30 shown) and pressure feet 22 sit in proximity to the carotid arteries.

-20-

The pressure feet 22 are caused to come into contact with the carotid arteries by activation of voice coil activators 20 which are operated by voice coil drivers 5 27. The voice coil drivers are controlled by controller 26. The controller also receives current feedback 25 as well as feedback from pressure sensor 24, which is associated with the mechanical feet. The activation of the voice coil actuators will be controlled by 10 measurement of pressure level feedback 30. There is also a processor 3 which monitors heart rhythm. In addition an ECG monitor gives an indication of the heart rhythm. When R-wave is detected and R-wave trigger 28 causes pulse generation 29 by way of the controller 26.

15

One or both of the supports of the pressure foot 22, usually in the form of a sac in which the pressure foot is contained, will contain a pressure transducer that produces feedback to control the voice coil pressure 20 actuator. Feedback will ensure that the stroke length of the actuator does not produce overpressure. Additionally there is an opportunity within the feedback loop to optimise the pressure impulse shape.

25 Independent voice coil actuators will compensate for asymmetric hydraulic transmission from neck to carotid sinus.

The pressure sensors in the sacs will also serve as a 30 pulse detector to enable optimum positioning over the carotid sinuses.

-21-

Safe control of the pressure pulse amplitude will be managed through the feedback system and by monitoring the voice coil actuating current.

5

Analysis of the HRT sequences will be performed using the ECG data.

As can be seen, the arrangement of the invention has particular features to ensure safety of operation. Other features that ensure safety are those which minimise the risk of electric shock, for example the voice coil pressure driver is a low voltage device (12v-24v). Isolation of the control system with medical grade design meeting IEC 60601-1 requirements will minimise electric shock issues. Also it is preferred that the ECG recording circuit is isolated and is powered by batteries or medical grade power supplies.

Further carotid sinus pressure is avoided by the incorporation of a pressure sensor within the pressure transmission fluid and feedback controlling signal to actuator driver. Also it is possible to incorporate an additional driver current monitoring circuit or actuator limit detectors or actuator current damping.

Further, the device is preferably biocompatible with individuals and is made of medical grade material to reduce the risk of allergic reaction.

30

Finally, patient trauma is minimised by selecting patients with ultrasound pre-scan to evaluate the suitability of patients with carotid plaque. Also there

-22-

is heart rate monitoring derived from sac pressure sensor and ECG sensor.

The invention covers not only individual embodiments as  
5 discussed but combinations of embodiments as well. It is  
to be understood that modifications and variations of the  
present invention will become apparent to those skilled  
in the art and it is intended that all such modifications  
will be included within the scope of the present  
10 invention.

Claims

1. A device for altering cardiac activity, said device  
5 comprising a neck engaging member, said neck engaging member having at least one pressure applicator provided as a predefined area which in use comes into contact with and occludes or partially occludes at least one carotid artery, said device including a control mechanism which  
10 is operable to cause the pressure applicator to rapidly occlude or partially occlude the at least one carotid artery in order to provoke heart rate turbulence.
2. A device according to claim 1, wherein the device  
15 includes a control mechanism that causes the pressure applicator to occlude or partially occlude the at least one carotid artery and release therefore after a predetermined period of time.
- 20 3. A device according to claim 1 or claim 2, wherein the occlusion or partial occlusion of the at least one carotid artery is achieved within one or more milliseconds.
- 25 4. A device according to claim 1 or claim 2, wherein occlusion or partial occlusion of the at least one carotid artery is achieved within 5 to 20 milliseconds.
- 30 5. A device according to claim 3 or claim 4, wherein the occlusion or partial occlusion has a duration for one or more cardiac cycles.

-24-

6. A device according to any preceding claim, when dependent on claim 1, wherein the neck engaging member device comprises a cuff that is placed around the neck of  
5 the individual, with the pressure applicator being aligned with the at least one carotid artery.

7. A device according to claim 6, wherein the pressure applicator is an inflatable balloon that when inflated  
10 occludes or partially occludes the at least one carotid artery.

8. A device according to claim 6, wherein the pressure applicator is a mechanical foot that comes into contact  
15 with and occludes or partially occludes the at least one carotid artery.

9. A device according to any of claims 1 to 5, wherein the neck engaging member comprises one or more mechanical  
20 arms that come into contact with the one or more carotid arteries.

10. A device according to any preceding claim, wherein the neck engaging member includes a pressure sensor,  
25 which detects the carotid pulse when the pressure applicator is positioned over the carotid artery.

11. A device according to any of claim 1 to 8, wherein the neck engaging member includes visible indicators so  
30 that the neck engaging member can be aligned with the carotid artery.

-25-

12. A device according to any preceding claim, wherein the pressure applicator is a mechanical foot that is brought into contact with the at least one carotid  
5 artery.

13. A device according to any preceding claim including a cardiac monitoring sensor to detect the R-wave associated with cardiac activity.

10

14. A device according to claim 13, wherein the cardiac monitoring sensor is in communication with an actuator that is operable to cause the pressure applicator to come into contact with the at least one carotid artery  
15 following detection of the R-wave.

15. A device according to claim 14, wherein activation of the actuator is triggered by detection of the R-wave followed by which the actuator is caused to release so  
20 that zero pressure is applied to the at least one carotid artery.

16. A device according to claim 14 or claim 15, wherein the actuator is a voice coil actuator.

25

17. A device according to any preceding claim, wherein the device includes a pressure measuring device that monitors the pressure of the pressure applicator against the carotid artery.

30

18. A device according to claim 17, wherein the pressure measuring device is a manometer.

-26-

19. A device according to any preceding claim, including a control system that can receive a pressure feedback signal from the pressure measuring device so that said  
5 signal can be compared with a reference signal.

20. A device according to any preceding claim, wherein the reference signal is stored as a value within predetermined safety levels for pressure that can be  
10 applied to the carotid artery.

21. A device according to any preceding claim, including a limited for the current to the actuator so that the pressure applied to the carotid artery is limited by  
15 reduction of the current.

22. A device according to any preceding claim including an ultrasound doppler probe.

20 23. A device according to any preceding claim including a timer device.

24. A device according to any preceding claim arranged to occlude or partially occlude more than one carotid  
25 artery.

25. A device according to any preceding claim to alter the heart rate of animals or humans.

30 26. A method of occluding the carotid artery, said method comprising applying a neck engaging member to an individual's neck such that at least one pressure applicator provided as a predefined area comes into

-27-

contact with at least one carotid artery, operating a control mechanism to cause the pressure applicator to rapidly occlude or partially occlude the at least one carotid artery in order to provoke heart rate turbulence.

5

27. A method according to claim 26, wherein the control mechanism is caused to occlude or partially occlude the at least one carotid artery and release therefore after a predetermined period of time.

10

28. A method according to claim 23 or 24, wherein the device is caused to occlude or partially occlude the at least one carotid artery within between 5 and 20 milliseconds for a duration of one or more cardiac cycles.

15

29. A device for altering cardiac activity as substantially described herein with reference to the accompanying figures.

20

30. A method for altering cardiac activity as substantially described herein with reference to the accompanying figures.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7a




FIG. 7b




FIG. 8

# INTERNATIONAL SEARCH REPORT

International application No  
PCT/GB2007/002716

|   |   |                           |
|---|---|---------------------------|
| <b>A. CLASSIFICATION OF SUBJECT MATTER</b><br>INV. A61B5/00   |   |                           |
| According to International Patent Classification (IPC) or to both national classification and IPC   |   |                           |
| <b>B. FIELDS SEARCHED</b>   |   |                           |
| Minimum documentation searched (classification system followed by classification symbols)<br>A61B   |   |                           |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched   |   |                           |
| Electronic data base consulted during the international search (name of data base and, where practical, search terms used)<br>EPO-Internal  |   |                           |
| <b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>   |   |                           |
| Category*   | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.     |
| X   | US 2005/004477 A1 (FRIEDMAN BRUCE ARNOLD [US] ET AL) 6 January 2005 (2005-01-06)<br><br>paragraphs [0017], [0018], [0020] - [0025], [0029]  | 1-15,<br>17-25,<br>29, 30 |
| X   | US 5 904 654 A (WOHLMANN WILLIAM J [US] ET AL) 18 May 1999 (1999-05-18)<br>column 2, line 53 - column 3, line 13  | 1, 29, 30                 |
| X   | EP 1 338 242 A (COLIN CORP [JP])<br>27 August 2003 (2003-08-27)<br>column 9, lines 1-40   | 1, 8, 9,<br>12, 29, 30    |
| -/--  |   |                           |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C.  |   |                           |
| <input checked="" type="checkbox"/> See patent family annex.  |   |                           |
| * Special categories of cited documents :   |   |                           |
| *A* document defining the general state of the art which is not considered to be of particular relevance<br>*E* earlier document but published on or after the international filing date<br>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)<br>*O* document referring to an oral disclosure, use, exhibition or other means<br>*P* document published prior to the international filing date but later than the priority date claimed | *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<br>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone<br>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.<br>*&* document member of the same patent family |                           |
| Date of the actual completion of the international search<br><br><p style="text-align: center;">5 December 2007</p>   | Date of mailing of the international search report<br><br><p style="text-align: center;">14/12/2007</p>   |                           |
| Name and mailing address of the ISA/<br>European Patent Office, P.B. 5818 Patentlaan 2<br>NL - 2280 HV Rijswijk<br>Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,<br>Fax: (+31-70) 340-3016   | Authorized officer<br><br><p style="text-align: center;">Martelli, Luca</p>   |                           |

## INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2007/002716

| C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT |   |                                    |
|--|---|------------------------------------|
| Category*  | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.              |
| X  | US 6 802 814 B2 (NARIMATSU KIYOYUKI [JP])<br>12 October 2004 (2004-10-12)<br><br>column 3, line 40 - column 5, line 13<br>-----                               | 1-12,<br>17-20,<br>22-25,<br>29,30 |
| X  | US 5 099 853 A (UEMURA MASAHIRO [JP] ET<br>AL) 31 March 1992 (1992-03-31)<br>column 1, lines 12-59<br>column 2, lines 27-42<br>column 3, lines 25-28<br>----- | 1,16,29,<br>30                     |

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB2007/002716

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 26-28  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box II.1

Claims Nos.: 26-28

The claims 26-28 include the steps of occluding the carotid artery by applying pressure on it in order to provoke heart rate turbulence. Such treatment of the human or animal body is considered as a method of treatment of the body by surgery and therefore as subject-matter on which the International Search Authority is not required to carry out search or preliminary examination (Rule 39.1(iv) PCT).

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2007/002716

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date   |
|--|------------------|-------------------------|--|
| US 2005004477                          | A1               | 06-01-2005              | NONE   |
| US 5904654                             | A                | 18-05-1999              | AU 7390596 A<br>WO 9714355 A2  |
| EP 1338242                             | A                | 27-08-2003              | CA 2417831 A1<br>JP 2003260033 A<br>US 2003163051 A1                             |
| US 6802814                             | B2               | 12-10-2004              | EP 1336374 A1<br>JP 2003235816 A<br>US 2003158489 A1                             |
| US 5099853                             | A                | 31-03-1992              | CA 1331788 C<br>DE 3787725 D1<br>DE 3787725 T2<br>EP 0297146 A1<br>WO 8804910 A1 |

|               |  |         |            |
|---------------|--|---------|------------|
| 专利名称(译)       | 用于改变心脏活动的装置和方法                                       |         |            |
| 公开(公告)号       | <a href="#">EP2051619A1</a>                          | 公开(公告)日 | 2009-04-29 |
| 申请号           | EP2007766284   | 申请日     | 2007-07-18 |
| 申请(专利权)人(译)   | UWS VENTURES LIMITED                                 |         |            |
| 当前申请(专利权)人(译) | UWS VENTURES LIMITED                                 |         |            |
| [标]发明人        | WILLSHAW PETER                                       |         |            |
| 发明人           | WILLSHAW, PETER                                      |         |            |
| IPC分类号        | A61B5/00   |         |            |
| CPC分类号        | A61B5/00 A61B5/02405 A61B5/411 A61B5/4884 A61B5/6822 |         |            |
| 优先权           | 2006014218 2006-07-18 GB                             |         |            |
| 外部链接          | <a href="#">Espacenet</a>                            |         |            |

#### 摘要(译)

一种用于改变心脏活动的装置，所述装置包括颈部接合构件，所述颈部接合构件具有至少一个压力施加器，所述压力施加器设置为预定区域，所述预定区域在使用中与至少一个颈动脉接触并闭塞或部分闭塞至少一个颈动脉。包括控制机构，该控制机构可操作以使压力施加器快速闭塞或部分闭塞动脉，以引起心率紊乱。